logo
EXCLUSIVE Doctors issue warning over drug taken by 150m that causes people to put on 10lbs

EXCLUSIVE Doctors issue warning over drug taken by 150m that causes people to put on 10lbs

Daily Mail​03-05-2025
Millions of Americans taking a common drug are twice as likely to become obese, a major study revealed.
One in 10 Americans take antidepressants and rely on them to reduce anxiety, ease depression and improve overall mental health.
However, the pills could come at the cost of another health crisis.
Tracking over 3,000 adults, Spanish researchers found people who took antidepressants for six years on average gained up to twice more body weight than non-users.
And even after accounting for diet, exercise and overall mental health, the drugs' effects compounded over time.
Roughly one in four people in the study gained more than five percent of their body weight - an increase medically linked to a heightened risk of diabetes, heart disease, and joint problems.
Participants who started taking antidepressants during the study gained an additional three percent of their total body weight, while long-term users (already on the drugs at the start of the study) gained two percent.
Dr Gabriela Lugón, a researcher at the Hospital del Mar and Pompeu Fabra University in Barcelona, said: 'We cannot simply prescribe antidepressants for their positive effects without also considering this side effect.'
Depression affects roughly 21 million Americans and anxiety strikes 40 million, making them two of the most common mental health disorders in the country.
Selective serotonin reuptake inhibitors (SSRIs), the most common type of antidepressants, whose side effects include weight gain, are prescribed to treat both by increasing levels of mood-regulating hormone serotonin.
While today's antidepressants work better and cause fewer side effects than older versions, all still come with downsides — both right away and over time. Common issues include sleep problems, dizziness, digestive troubles, sexual dysfunction, and— critically — weight gain.
Unwanted pounds are a top reason people stop taking these medications, forcing doctors and patients to constantly weigh the pros and cons.
Dr Víctor Pérez, head of the Psychiatry Department at Hospital del Mar, said that while the drugs are highly effective, 'their effect on weight is not universal, although certain medications, such as mirtazapine and paroxetine, can cause significant weight gain.'
Researchers recruited 6,352 adults ages 35 to 79 from northeastern Spain in 2005 and followed them for six years.
Participants were divided into four groups based on their antidepressant use: never used, new users starting during the study, quit users (stopped by the time of follow-up) and long-term users who were already on antidepressants when the study started and continued taking them through the six-year follow-up.
Nurses recorded each person's weight and height at the start of the study, as well as their diet (using the Mediterranean diet as the standard), exercise habits, symptoms of depression, smoking history, diabetes status and blood pressure.
The researchers wanted to focus specifically on the percent body weight gain and the number of new obesity cases characterized by a body mass index (BMI) of 30 or higher.
Every study participant gained weight, whether they were taking antidepressants or not, but those who were taking antidepressants gained more.
On average, never users gained 0.8 percent of their body weight. Those who discontinued use gained 2.2 percent and new users gained 2.5 percent. Long-term users gained 1.7 percent.
This means antidepressant users gained at least twice the amount of weight as those who never took the drugs.
Dr Camille Lassale, a researcher at the Hospital del Mar Research Institute, said: 'All individuals taking antidepressants had a higher likelihood of gaining weight and developing obesity. This risk is even greater for those who use these medications continuously.'
Experts do not know for sure why antidepressants cause weight gain, but serotonin is the link.
Most antidepressant medications, such as Prozac, Zoloft, Effexor, and Cymbalta, alter levels of serotonin in the brain to regulate mood and emotion.
SSRIs block the reabsorption of serotonin so that more of this 'good mood' chemical stays in the brain, while serotonin-norepinephrine reuptake inhibitors block the reabsorption of serotonin as well as norepinephrine, an energy-regulating chemical.
The neurotransmitter that regulates mood and anxiety levels also acts like a traffic light for hunger.
After first starting an SSRI, the brain experiences a boost in serotonin, which reduces impulsivity and increases satiety, leading the person taking the medicine to eat less.
But after about a year on the medication, the brain begins to adapt by turning down receptors in the brain that serotonin clings to, creating what is known as serotonin resistance.
This causes the body to crave a quick fix in the form of carbs or sweets, which temporarily boost serotonin levels while leading to weight gain over time.
Dr Pérez said: 'Due to the risk of patients discontinuing treatment because of weight gain, we must consider alternative therapeutic strategies to complement pharmacological treatment.'
But doctors caution against abruptly stopping an antidepressant regimen without the input of a doctor, who typically tapers the patient off the medicine gradually over several weeks to avoid withdrawal symptoms, some of which can be severe.
They include flu-like aches, dizziness, mood swings, sleep problems, and 'brain zaps,' referring to feelings of electric shocks shooting through the head.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

You can now give yourself an at-home flu vaccine
You can now give yourself an at-home flu vaccine

The Independent

time4 hours ago

  • The Independent

You can now give yourself an at-home flu vaccine

For the first time, Americans can get their seasonal flu vaccine at home. Starting Friday, eligible adults in 34 states can order the FluMist Home - a nasal spray - online ahead of the upcoming flu season, European drugmaker AstraZeneca announced, calling it a 'transformational moment in the evolution of influenza protection.' FluMist was previously only available at pharmacies or doctors' offices. Now, interested people can go to to order the sprays, potentially saving time spent at a clinic or drug store. Once received, the vaccine should be stored in the refrigerator until it is used. Then, people between the ages of 18 and 49 years old can self-administer the vaccine. FluMist Home can be given to children and teens between the ages of two and 17 years old. A full dose is one spray in each nostril. FluMist may not prevent infection in everyone who takes it, but it works similarly to vaccines for measles and chickenpox. It contains weakened versions of viruses that trigger the immune system in the nose and throat, teaching it to build up immunity without causing infection. In rare cases, FluMist may cause serious side effects, including allergic reactions. But the most common side effects are a runny or stuffy nose, a sore throat and a fever of over 100 degrees. Some people should not take FluMist, including those with severe allergies to eggs, the vaccine's ingredients, or other flu vaccines, and kids who take aspirin or medicines containing aspirin. Children should also not take aspirin for four weeks after they get FluMist, unless told to do so by a healthcare provider. The spray, which was initially approved by the Food and Drug Administration in 2003 and was approved for at-home use without a healthcare professional last September, should be free for people with insurance, though there is an $8.99 shipping and processing fee. AstraZeneca said it hopes that all of the lower 48 states will have access to the spray in future flu seasons, although when that may be is unclear. The announcement comes on the heels of the worst flu season in 15 years, fueled by a cold winter, the spread of H5N1 bird flu, Covid, and other respiratory illnesses, and declining vaccine rates. Falling vaccination was 'a major cause of the surge,' Dr. Elizabeth Mack, the head of the pediatric critical care unit at the Medical University of South Carolina's Children's Health, told National Geographic. 'As influenza vaccination rates decline, especially among younger populations, this first-of-its-kind, at-home, needle-free option offers a critical opportunity to help make protection more accessible, convenient, and better aligned with the realities and current preferences of people's lives,' Dr. Ravi Jhaveri, the division head of infectious diseases at Northwestern University School of Medicine, said of FluMist Home, in a statement shared by AstraZeneca.

Soaring melanoma rates scared me out of tanning. Here's how I stay stylish in the sun
Soaring melanoma rates scared me out of tanning. Here's how I stay stylish in the sun

Telegraph

time11 hours ago

  • Telegraph

Soaring melanoma rates scared me out of tanning. Here's how I stay stylish in the sun

Sunbathing. That sweaty, now dirty sport, long associated with wealth, leisure and languid Mediterranean summers. I vividly remember my sister and I soaking our hair in lemon and buttering our limbs and faces in baby oil, then positioning ourselves like seasoned potatoes on the lawn. There was scant regard for sun safety on holiday, even as a child, where we'd routinely singe faces by the pool and as a teen, anchor there for hours on end, with the sole goal of discovering a tan line before supper. So crucial was a sun-kissed glow to our social cred that I once had to rescue a friend who'd fainted in a sun bed pod (we'd fibbed about our age in the tanning shop and risked dehydration in feverish pursuit of that golden hue). Summer wardrobes reflected this – we'd go bare-legged and bare-shouldered to maximise our tans, and flaunt our hours on the sun lounger thus far. Wide-brimmed sun-hats were too shady for the last two decades of dedicated sun-bathers – and baseball caps had yet to spill over from tennis courts or golf courses. Linen dresses were short and often sleeveless – and stringy, dental floss bikinis were designed to expose as much flesh as possible, resting precariously above pubic bones and just below the nipple. Then came the gradual but seismic shift. The dangers of too much sun exposure were laid bare in the 2010s, fuelled by skin cancer statistics (malignant melanoma quadrupling for Britons from 1980) and the beauty industry casting ultraviolet radiation as the ultimate ageing villain, etching wrinkles into skin prematurely with added pigmentation issues. You'd be a maverick, a fool, 15 years ago, to forego a poolside sizzle for a long sarong and wide-brimmed hat. But the factor-50 sunscreen anxiety, perma-hat and long-sleeved kaftan antics on a recent holiday confirmed this shift. In 2025, sun-worshipping elicits the same level of disdain as smoking outside a New York restaurant or nursing a morning rosé on a commuter train. In fact, the entire holiday formula, that once rested primarily on sunbathing schedules, has been turned on its head – shade and skin health now call the shots. That's not to say you can't wallow in the mottled shallows under the midday sun, or tuck into a Dolce Vita al fresco lunch. It's all there for the taking, just with thick SPF, a wide-brimmed hat and Anne Hathaway-level dedication to full limb sun protection (see her toddler-rash-vest-inspired swim set in which she was recently pictured in Italy). Sunburn is not only considered irresponsible now but the very nadir of our post-Tango'd society. Designers have observed this cultural pendulum swing too, citing demand for breathable fabrics that protect the skin. 'There's definitely a move towards pieces that cover more while still feeling light,' says Wiggy Kit founder, Wiggy Hindmarch. 'Women are investing in timeless, well-made pieces that offer coverage while still feeling airy and elegant – and pieces that can be thrown over a swimsuit as easily as they can be worn into town for lunch.' Sales of linen in particular have been boosted by the anti-UV movement. 'We're seeing a quiet move towards pieces that feel breezy and unrestrictive, while still offering a sense of refinement,' says Marianne McDonald, creative director of Citizens of Humanity. 'Our Brynn linen trousers can transition seamlessly from poolside lounging to lunch.' Linen specialist Kindred of Ireland's founder, Amy Anderson, echoes this: 'We've seen a growing demand for long-sleeved linen shirts and easy, breathable dresses that offer both elegance and sun protection,' she says. Indeed, I now wear Kindred's striped linen over swimwear in summer, easily stripped off for a dip in the sea. It's a stylish, breezy alternative to sticky sun cream, as are long-sleeved rash vests (Hunza G has a front-zip one, as has Free People, both made from UV-protective technical material). Meanwhile, business is booming for UPF straw hat brands such as Australian brands Helen Kaminski and Lorna Murray. Dermatologists swear by Eric Javits UPF 50 hats, and sunglasses have more of a year-round presence, where maximum UV protection and style must work in tandem. I see my friends dressing for sunny days in floaty, sleeved dresses from Doen, gingham nighties by If Only If, and accessorising with costume jewellery by YSSO and So-Le Studio. Long skirts have had a comeback (M&S currently has a knockout denim offering) which pair like fine wine with summery blouses from Smock London, Sezane and Herd. I'm also loving the sarong revival spearheaded by brands such as Alvica and Pucci, which tastemakers are styling as low-slung belts over dresses or trousers, as skirts paired with T-shirts, or flung over bare shoulders. My favourite look is the latter, to wake up a plain linen dress. We may be a fair few steps away from Anne Hathaway's full-coverage summer commitment, but there's no denying that the seared skin tanning age (and accompanying 'resort wear') has run its course. I for one am thrilled to be stepping into the era of rash vests, headwear and long-sleeved linen, layered with statement jewellery and laced with a smug disregard for the weather. The new summer wardrobe

Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer

Daily Mirror

timea day ago

  • Daily Mirror

Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer

Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. ‌ The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. ‌ The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. ‌ Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. ‌ Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. ‌ The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store